Skip to content

Magnesium sulphate ( magsalf) for fetal neuroprotection.

ââ?¬Å?Magnesium sulfate ( MAGSALF) for fetal neuroprotection given in spontaneous preterm birth versus magnesium sulfate for hypertensive disorder of pregnancy versus preterm newborn not receiving magsalf ââ?¬â?? A comparative prospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019293
Enrollment
1424
Registered
2019-05-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O368- Maternal care for other specifiedfetal problems

Interventions

Intervention1: Magnesium sulfate: dose : 4 gram route :intravenous frequency : stat Control Intervention1: magnesium sulphate more than 4 gram: loading dose : 14 gram ( 4 gram intravenous followed

Sponsors

King Georges Medical University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women with established preterm labour (regular uterine contraction with cervical dilatation of �4 cm )at gestational age of less than 32 weeks. 2. Women requiring iatrogenic preterm labour / cesarean at gestatonal age less than 32 weeks 3. Women with severe pre-Eclampsia or Eclampsia having preterm labour being given magnesium sulphate at less than 32 weeks .

Exclusion criteria

Exclusion criteria: 1. Myasthenia gravis 2. Acute renal failure 3. False preterm 4. Gestational age more than 32 weeks

Design outcomes

Primary

MeasureTime frame
apgar, need mechanical ventilation/ tracheal Intubation, seizures, Necrotizing enterocolitis, NICU admission, intraventricular hemorrhage, periventricular leucomalacia, white matter injury Fetal imaging : USG / MRI Timepoint: Fetal outcome : apgar, need mechanical ventilation/ tracheal Intubation, seizures, Necrotizing enterocolitis, NICU admission, intraventricular hemorrhage, periventricular leucomalacia, white matter injury Fetal imaging : USG / MRI

Secondary

MeasureTime frame
To document long term effect (cerebral palsy, neurodevelopment delay)Timepoint: 2 yrs

Countries

India

Contacts

Public ContactNamrata Kumar

King Georges Medical University

dr.nmrata@gmail.com9415118848

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026